Association of a mineralocorticoid receptor gene polymorphism with hypertension in a spanish population

American Journal of Hypertension

Volumn 22, Issue 6, 2009, Pages 649-655

  Martinez, Fernando ^a,b   Mansego, Maria L ^c   Escudero, Juan C ^d   Redon, Josep ^a,b   Chaves, Felipe J ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MINERALOCORTICOID RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM URINE LEVEL; SPAIN;

AGED; ALLELES; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; RECEPTORS, MINERALOCORTICOID; SPAIN;

EID: 67349107880     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.39     Document Type: Article

References (42)

1. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22:239-247.
2. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton R P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289:119-123.
3. Riepe FG, Krone N, Morlot M, Ludwig M, Sippell WG, Partsch CJ. Identification of a novel mutation in the human mineralocorticoid receptor gene in a German family with autosomal-dominant pseudohypoaldosteronism type 1: further evidence for marked interindividual clinical heterogeneity. J Clin Endocrinol Metab 2003; 88:1683-1686.
4. Riepe FG, Finkeldei J, de Sanctis L, Einaudi S, Testa A, Karges B, Peter M, Viemann M, Grotzinger J, Sippell WG, Fejes-Toth G, Krone N. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 2006; 91:4552-4561.
5. Liu G, Grifman M, Keily B, Chatterton JE, Staal FW, Li QX. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem Biophys Res Commun 2006; 342:1291-1296.
6. Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens 2007; 9(1 Suppl 1):13-18.
7. Stowasser M, Gordon RD. Monogenic mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab 2006; 20:401-420.
8. Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology 2003; 144:528-533.
9. Pinon GM, Fagart J, Souque A, Auzou G, Vandewalle A, Rafestin-Oblin ME. Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension. Mol Cell Endocrinol 2004; 217:181-188.
10. Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME. The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. Mol Pharmacol 2005; 67:1714-1722.
11. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 2005; 12:554-555.
12. Sugiyama T, Kato N, Ishinaga Y, Yamori Y, Yazaki Y. Evaluation of selected polymorphisms of the Mendelian hypertensive disease genes in the Japanese population. Hypertens Res 2001; 24:515-521.
13. Tempfer CB, Jirecek S, Riener EK, Zeisler H, Denschlag D, Hefler L, Husslein PW. Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: a pilot study. J Soc Gynecol Investig 2004; 11:227-231.
14. Fernandes-Rosa FL, de Castro M, Latronico AC, Sippell WG, Riepe FG, Antonini SR. Recurrence of the R947X mutation in unrelated families with autosomal dominant pseudohypoaldosteronism type 1: evidence for a mutational hot spot in the mineralocorticoid receptor gene. J Clin Endocrinol Metab 2006; 91:3671-3675.
15. Riepe FG, Krone N, Morlot M, Peter M, Sippell WG, Partsch CJ. Autosomal-dominant pseudohypoaldosteronism type 1 in a Turkish family is associated with a novel nonsense mutation in the human mineralocorticoid receptor gene. J Clin Endocrinol Metab 2004; 89:2150-2152.
16. Nystrom AM, Bondeson ML, Skanke N, Martensson J, Stromberg B, Gustafsson J, Anneren G. A novel nonsense mutation of the mineralocorticoid receptor gene in a Swedish family with pseudohypoaldosteronism type I (PHA1). J Clin Endocrinol Metab 2004; 89:227-231.
17. Arai K, Tsigos C, Suzuki Y, Irony I, Karl M, Listwak S, Chrousos G P. Physiological and molecular aspects of mineralocorticoid receptor action in pseudohypoaldosteronism: a responsiveness test and therapy. J Clin Endocrinol Metab 1994; 79:1019-1023.
18. Arai K, Nakagomi Y, Iketani M, Shimura Y, Amemiya S, Ohyama K, Shibasaki T. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum Genet 2003; 112:91-97.
19. DeRijk RH, Wust S, Meijer OC, Zennaro MC, Federenko IS, Hellhammer DH, Giacchetti G, Vreugdenhil E, Zitman FG, de Kloet ER. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab 2006; 91:5083-5089.
20. -cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res 2004; 27:821-833.
21. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 2005; 46:758-765.
22. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de La Sierra. A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 2001; 38:1204-1209.
23. Munoz-Brauning CR, Carvajal CA, Mosso LM, Valdivia G, Fardella CE. Microsatellite marker AGAT of the mineralocorticoid receptor gene is associated with plasma renin activity in patients with essential hypertension. Rev Med Chil 2005; 133:1415-1423.
24. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, Wilson PW, Rifai N, Meigs JB, Ricken G, Lifton R P, Levy D, Vasan RS. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005; 18:657-665.
25. Kamide K, Yang J, Kokubo Y, Takiuchi S, Miwa Y, Horio T, Tanaka C, Banno M, Nagura J, Okayama A, Tomoike H, Kawano Y, Miyata T. A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes. Hypertens Res 2005; 28:703-709.
26. Wilk JB, Djousse L, Arnett DK, Hunt SC, Province MA, Heiss G, Myers RH. Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study. Am J Hypertens 2004; 17:839-844.
27. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens 2003; 21:1283-1289.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
29. Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, Hashimoto T: A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens 2002; 16:97-103.
30. Kawano Y, Tsuchihashi T, Matsuura H, Ando K, Fujita T, Ueshima H; Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. Hypertens Res 2007; 30:887-893.
31. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2005; 21:263-265.
32. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
33. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet 2008; 9:36.
34. Gordon D, Haynes C, Blumenfeld J, Finch SJ. PAWE-3D: visualizing power for association with error in case-control genetic studies of complex traits. Bioinformatics 2005; 21:3935-3937.
35. Gordon D, Finch SJ, Nothnagel M, Ott J. Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms. Hum Hered 2002; 54:22-33.
36. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96:434-442.
37. Kraft P. Efficient two-stage genome-wide association designs based on false positive report probabilities. Pac Symp Biocomput 2006:523-534.
38. Dudbridge F, Gusnanto A, Koeleman B P. Detecting multiple associations in genome-wide studies. Hum Genomics 2006; 2:310-317.
39. Chen SN, Ballantyne CM, Gotto AM, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45:1611-1619.
40. Lovatt T, Alldersea J, Lear JT, Hoban PR, Ramachandran S, Fryer AA, Smith AG, Strange RC. Polymorphism in the nuclear excision repair gene ERCC2/ XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma. Hum Mutat 2005; 25:353-359.
41. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 2007; 13:2621-2626.
42. Strange RC, El-Genidy N, Ramachandran S, Lovatt TJ, Fryer AA, Smith AG, Lear JT, Wong C, Jones PW, Ichii-Jones F, Hoban PR. Susceptibility to basal cell carcinoma: associations with PTCH polymorphisms. Ann Hum Genet 2004; 68:536-545.